Healio
Healio

Melanoma Video Perspectives

In a video interview, Vernon K. Sondak, MD, of Moffitt Cancer Center, discussed exciting treatment developments, cellular therapy, unmet needs in melanoma and more.

Choose a Section
  • Vernon K. Sondak, MD

    • Vernon K. Sondak, MD

    In a video interview, Vernon K. Sondak, MD, chair of the department of cutaneous oncology at Moffitt Cancer Center, discussed:

    • New roles of neoadjuvant therapy pre- and post-surgery;
    • Upcoming additional checkpoint inhibitors, stimulators in phase II and III clinical trials;
    • The "quiet revolution" in melanoma adaptive cellular therapy with tumor-infiltrating lymphocytes (TIL) and other immune therapies;
    • Effective, durable immune responses seen in a ‘cocktail’ of therapies, including IL-2, myelosuppressive preoperative chemotherapy;
    • The critical importance of identifying truly resistant patients and use of the TIL approach; and
    • A need to "tease out mechanisms of resistance" to provide appropriate treatments in patients.

    Read more about

    melanoma
    tumor infiltrating lymphocytes
    cell therapy
    You've successfully added to your alerts. You will receive an email when new content is published.

    Click Here to Manage Email Alerts

    We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.